title: Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
abstract: We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72-0.97). Lymphoma-related mortality (HR, 0.46; 0.23-0.93) and overall survival (HR, 0.63; 0.41-0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770-775, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Section of Hematology and Oncology, Department of Medicine, the University of Chicago.
authors.forename: Chadi
authors.initials: C
authors.lastname: Nabhan
authors.affiliation: Biometrics, RTI Health Solutions, North Carolina.
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Medical Affairs, Genentech, Inc, California.
authors.forename: Bann-Mo
authors.initials: BM
authors.lastname: Day
authors.affiliation: Medical Affairs, Genentech, Inc, California.
authors.forename: Keith
authors.initials: K
authors.lastname: Dawson
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.affiliation: James P Wilmot Cancer Center, the University of Rochester, New York.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Friedberg
authors.affiliation: Health Sciences Research, Mayo Clinic, New York.
authors.forename: James R
authors.initials: JR
authors.lastname: Cerhan
authors.affiliation: Department of Medicine, the University of Iowa, Iowa.
authors.forename: Brian K
authors.initials: BK
authors.lastname: Link
authors.affiliation: Winship Cancer Institute, Emory University, Georgia.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012042:Registries; D000069283:Rituximab / Q000627:therapeutic use; D012737:Sex Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D000069283:Rituximab